Clinical experience with fulvestrant, pure oestrogen receptor (ER) antagonist with no agonist effects, in pre-treated advanced breast cancer patients

被引：0
|
作者：
Menjon, S. S. M. [1 ]
Garcia, J. J. G. [1 ]
Gonzalez, E. E. G. [1 ]
机构：
[1] Hosp Virgen de las Nieves, Breast Canc Funct Oncol Unit, Granada, Spain
来源：
BREAST | 2009年 / 18卷
关键词：
D O I：
10.1016/S0960-9776(09)70207-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [1] CLINICAL EXPERIENCE WITH FULVESTRANT, PURE OESTROGEN RECEPTOR (RE) ANTAGONIST WITH NO AGONIST EFFECTS, IN PRE-TREATED ADVANCED BREAST CANCER PATIENTS
    Sanchez-Munoz, A.
    Blancas, I.
    Gonzalez, E.
    Martinez, A.
    Jaen-Morago, A.
    Porras, I.
    Carabantes, F.
    Canosa, L.
    de la Haba, J.
    Sanchez-Rovira, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 75 - 75
  • [2] Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience
    Steger, GG
    Bartsch, R
    Wenzel, C
    Pluschni, U
    Hussian, D
    Sevelda, U
    Locker, GJ
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) : 2655 - 2661
  • [3] Fulvestrant in heavily pre-treated patients with advanced breast cancer:: results from a single compassionate use programme centre
    Catania, Chiara
    Ascione, Gilda
    Adamoli, Laura
    De Pas, Tommaso
    Medici, Marta
    Franceschelli, Lucia
    Verri, Elena
    Magni, Elena
    Sanna, Giuseppina
    Torrisi, Rosalba
    Goldhirsch, Aron
    Nole, Franco
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (01) : 97 - 103
  • [4] Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre
    Chiara Catania
    Gilda Ascione
    Laura Adamoli
    Tommaso De Pas
    Marta Medici
    Lucia Franceschelli
    Elena Verri
    Elena Magni
    Giuseppina Sanna
    Rosalba Torrisi
    Aron Goldhirsch
    Franco Nolè
    Breast Cancer Research and Treatment, 2007, 106 : 97 - 103
  • [5] Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience
    Sanganalmath, P.
    Purohit, K.
    Winter, M.
    Horsman, J.
    Ramakrishnan, S.
    Hatton, M.
    Lee, C.
    Dunn, K.
    Din, O.
    Coleman, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S181 - S182
  • [6] Clinical experience with fulvestrant in pretreated patients with advanced breast cancer.
    Menjon Beltran, S.
    Garcia Garcia, J., Sr.
    Gonzalez Flores, E.
    Conde Herrero, V.
    Gonzalez Jimenez, E., Sr.
    Gutierrez Lomas, V., Sr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Clinical experience with eribulin and trastuzumab in significantly pre-treated patients with hepatically metastasized breast cancer
    Luedders, D. W.
    Gembicki, M.
    Bernhardt, M.
    Rody, A.
    Bohlmann, M. K.
    ONKOLOGIE, 2013, 36 : 159 - 159
  • [8] FULVESTRANT - A NOVEL ESTROGEN RECEPTOR ANTAGONIST FOR THE TREATMENT OF ADVANCED BREAST CANCER
    Buzdar, Aman U.
    DRUGS OF TODAY, 2008, 44 (09) : 679 - 692
  • [9] Fulvestrant - A new type of estrogen receptor antagonist for the treatment of advanced breast cancer
    Buzdar, AU
    DRUGS OF TODAY, 2004, 40 (09): : 751 - 764
  • [10] Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Addamo, G.
    Colloca, G.
    Venturino, A.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 279 - 279
12345